Rebecca S. Hock, PhD, is affiliated with the Clinical Trials Network and Institute, Department of Psychiatry at Massachusetts General Hospital, and the Department of Psychiatry at Harvard Medical School. Her published work focuses on major depressive disorder (MDD), including studies on intranasal esketamine, vortioxetine, and antidepressant use in community samples. She has contributed to systematic reviews, meta-analyses, and clinical trial analyses related to the treatment and epidemiology of depression. Her research has appeared in Psychiatrist.com between 2014 and 2022.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
